Drugs / SBS-1000
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05721287 Comparator | Jan → Aug 2023 | — | Sparian Biosciences, Inc | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | Sparian Biosciences, Inc | Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000 sparianbiosciences.com ↗ |
| 2023-02-23 | Sparian Biosciences, Inc | Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain sparianbiosciences.com ↗ |
| 2023-02-09 | Sparian Biosciences, Inc | Sparian Biosciences Announces IND Clearance of First-In-Class Arylepoxamide Agonist, SBS-1000, for the Treatment of Pain by the U.S. FDA sparianbiosciences.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBS-1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05721287 ↗ |
| Action | Activate | “arylepoxamide agonist” NCT05721287 ↗ |
| Route | Intravenous | “SBS-1000 administered as a single continuous IV infusion over 60 minutes” NCT05721287 ↗ |